The global schizophrenia treatment market value is expected to undergo a modest increase over the coming decade...
The global schizophrenia treatment market value is expected to undergo a modest increase over the coming decade, climbing from $6.3 billion in 2012 to $7.9 billion by 2022, at a Compound Annual Growth Rate (CAGR) of 2.4%, according to a new report from research and consulting firm GlobalData.
The company’s latest report* states that out of the seven major markets (7MM: the US, France, Germany, Italy, Spain, the UK and Japan), the US dominated the schizophrenia space in 2012 with sales of $5.2 billion and a global share of 83%. It will maintain its market-leading position by 2022 with sales of $6.1 billion, representing a CAGR of 1.6% during the forecast period.
GlobalData attributes the anticipated market expansion to a rising awareness of mental health, along with increasing utilization of long-acting injectable (LAI) antipsychotics and various new product launches.
Among the drugs that are due to enter the market during the forecast period are Otsuka’s brexpiprazole, Roche/Chugai’s bitopertin, EnVivo’s EVP-6124, Alkermes’ aripiprazole lauroxil and Johnson & Johnson’s (J&J) Invega Sustenna (Three-Month).
Kyle Nicholson, PharmD, GlobalData's Analyst covering Neurology, says: “These latter two drugs will introduce new LAI treatments and expand the global market options by 33%. The three-month version of J&J’s Invega Sustenna in particular will provide patients with a reduced dosing burden.
“As novel products in an emerging part of the schizophrenia drug market, these agents could be met with significant sales, due to their higher costs of therapy and a growing popularity of LAIs in this space.”
However, such costs may well push patients toward generic alternatives, subsequently hindering any further growth in the global schizophrenia market, according to GlobalData.
Furthermore, the level of unmet need in schizophrenia and related mental health disorders is one of the highest in medicine today, presenting another significant barrier to the market.
Nicholson continues: “Schizophrenia treatment currently consists of first-generation antipsychotics and atypical therapies, which do not adequately satisfy patients’ needs.
“While the pipeline boasts several candidates targeting negative and cognitive symptoms, in addition to a number of LAI therapies, the fierce competition surrounding the schizophrenia market means these products will have to demonstrate that their utility surpasses those of currently marketed options,” the analyst concludes.
*PharmaPoint: Schizophrenia – Global Drug Forecast and Market Analysis to 2022
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Managing Side Effects and Dosing in Off-Label GLP-1 Use with Help from Real-World Evidence
July 18th 2025Shipra Patel, global therapeutic area section head, endocrinology, global head, pediatrics, Parexel, explains how real-world data is helping researchers navigate gastrointestinal side effects, dose flexibility, and long-term tolerability in off-label GLP-1 use.
Anselamimab Misses Primary Endpoint in Phase III CARES Trials for AL Amyloidosis
July 17th 2025In the Phase III CARES trials, anselamimab did not meet the primary endpoint for advanced-stage AL amyloidosis, but a prespecified subgroup analysis revealed meaningful improvements in survival and cardiovascular outcomes.